TITLE

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study

AUTHOR(S)
Kumar, Subodh; Chaudhury, Suprakash
PUB. DATE
January 2014
SOURCE
Industrial Psychiatry Journal;Jan-Jun2014, Vol. 23 Issue 1, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Negative symptoms and diminished cognitive ability are also considered as core features of schizophrenia. There are many studies in which negative symptoms and cognitive impairments are individually treated with atypical antipsychotic in comparison with either a placebo or a typical antipsychotic. There is paucity of studies comparing the efficacy of olanzapine and amisulpride on improvement of negative symptoms and cognitive impairments. Aim: To examine the effectiveness of amisulpride and olanzapine in treatment of negative symptoms and cognitive impairments in schizophrenia. Materials and Methods: Total 40 adult inpatients diagnosed as schizophrenia fulfilling inclusion/exclusion criteria were included in the study with their informed consent. These patients were recruited consecutively to one of the two drug regimen group, i.e. tab Amisulpride (100-300 mg/day) and tab Olanzapine (10-20 mg). Patients were evaluated on day 0 and day 60 with various rating scales like Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Schizophrenia Cognition Rating Scale (SCoRS), Brief Psychiatric Rating Scale (BPRS), Calgary Depression Scale for Schizophrenia (CDSS), and three different scales to measure drug side effects. Results: The mean SANS score in amisulpride and olanzapine group at day 0 and day 60 were 83.89 (±12.67) and 21.00 (±11.82) and 84.40 (±13.22) and 26.75 (±12.41), respectively. The mean rank of SCoRS global in amisulpride and olanzapine group at day 0 and day 60 were 4.78 (±1.13) and 2.78 (±0.63) and 4.85 (±1.18) and 3.30 (±1.12), respectively. The percentage improvement in SANS, SAPS, SCoRS interviewer, and SCoRS global in amisulpride group are 74.96%, 13.36%, 54.14%, and 42.00%, respectively. Similarly in olanzapine group percentage improvement in SANS, SAPS, SCoRS interviewer, and SCoRS global are 68.30%, 30.28%, 35.22%, and 31.95%, respectively. There is significant improvement in SANS, SCoRS, SAS, BPRS, and PANSS (Insight) in both amisulpride and olanzapine groups at the two time points. However, there is no significant difference between amisulpride and olanzapine group of patients. Conclusion: Both amisulpride and olanzapine group patients showed significant improvement in negative and cognitive symptoms from baseline to endpoint, but there was no significant difference between amisulpride and olanzapine group of patients.
ACCESSION #
99814580

 

Related Articles

  • Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review. Hai Bo Haber Xue; Li Liu; Hena Zhang; Montgomery, William; Treuer, Tamás // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p841 

    Background: Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety...

  • Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China. Wenyu Ye; Montgomery, William; Kadziola, Zbigniew; Li Liu; Haibo Xue; Stensland, Michael D.; Treuer, Tamas // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p869 

    Background: The aims of this analysis were to identify factors associated with early response (at 4 weeks) to olanzapine treatment and to assess whether early response is associated with better longer-term outcomes for patients with schizophrenia in the People's Republic of China. Methods: A...

  • Rapid Leptin Elevation after Initiation of Olanzapine? Hsuan-Chi Wang; Po See Chen; I Hui Lee; Yen Kuang Yang; Tzung Lieh Yeh; Ru-Band Lu // Neuropsychobiology;2006, Vol. 54 Issue 3, p182 

    Weight gain is a common adverse effect associated with olanzapine treatment. Another side effect of olanzapine treatment is a significant increase in circulating leptin levels. This preliminary study monitored the changes in leptin levels for 2 weeks after olanzapine treatment had been...

  • Amisulpride/levosulpiride/olanzapine/risperidone.  // Reactions Weekly;Nov2014, Vol. 1527 Issue 1, p29 

    The article presents case studies of two men and three women who developed tardive syndromes during treatment with the antipsychotics amisulpride, levosulpiride, olanzapine or risperidone.

  • Loxapine P-glycoprotein Interactions In Vitro. Reed, Andrea; Huie, Keith; Perloff, Elke S.; Cassella, James V.; Takahashi, Lori H. // Drug Metabolism Letters;Mar2012, Vol. 6 Issue 1, p26 

    The antipsychotic drugs risperidone, paliperidone, olanzapine, quetiapine, aripiprazole, clozapine, haloperidol, and chlorpromazine have been reported to have various degrees of interaction (substrate or inhibitor) with the multidrug resistance transporter, P-glycoprotein (P-gp). An interaction...

  • Study Suggests Means to Control Chemotherapy's Side Effects.  // Ascribe Newswire: Medicine;6/8/2004, p141 

    Since the mid-1990s, a drug called olanzapine has been used to treat schizophrenia and other psychoses. Now, a team of scientists led by a University of Notre Dame cancer researcher has found a new use for the drug that may make chemotherapy treatments far less onerous. Rudolph M. Navari,...

  • Intramuscular olanzapine: a review of its use in the management of acute agitation. Wagstaff, Antona J.; Easton, Jane; Scott, Lesley J. // CNS Drugs;2005, Vol. 19 Issue 2, p147 

    Intramuscular olanzapine (Zyprexa) is a rapid-acting atypical antipsychotic drug that is also indicated for use in patients with agitation associated with schizophrenia or bipolar mania, the focus of this review. Evidence from three well designed trials indicates that this formulation of...

  • Formulation and In-vitro Evaluation of Orally Disintegrating Tablets of Olanzapine-2-Hydroxypropyl-ß-Cyclodextrin Inclusion Complex. Shankarrao, Kulkarni Ajit; Mahadeo, Ghadge Dhairysheel; Balavantrao, Kokate Pankaj // Iranian Journal of Pharmaceutical Research;Dec2010, Vol. 9 Issue 4, p335 

    The aim of this study was to design orally disintegrating tablets of Olanzapine and to complex Olanzapine with 2-hydroxypropyl-β- cyclodextrin with special emphasis on disintegration and dissolution studies. Phase solubility studies demonstrated the formation of 1:1 molar inclusion complex by...

  • Olanzapine Treatment in Choreoathetosis due to Bilateral Striopallidodentate Calcinosis. Balaban, Hatice; Sahiner, Turker; Degirmenci, Eylem // Klinik Psikofarmakoloji Bulteni;Dec2004, Vol. 14 Issue 4, p209 

    Olanzapine treatment in choreoathetosis due to bilateral striopallidodentate calcinosis Bilateral Idiopathic Striopallidodentate Calcinosis (BISPDCs) refers to idiopathic calcification of the basal ganglia and secondary striato-dentate calcinosis. Its definition comprises numerous metabolic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics